WO2023128197A1 - Composition pour soulager, prévenir ou traiter la sarcopénie, comprenant un extrait de germe de cacahuète de jeju udo en tant que principe actif - Google Patents

Composition pour soulager, prévenir ou traiter la sarcopénie, comprenant un extrait de germe de cacahuète de jeju udo en tant que principe actif Download PDF

Info

Publication number
WO2023128197A1
WO2023128197A1 PCT/KR2022/016542 KR2022016542W WO2023128197A1 WO 2023128197 A1 WO2023128197 A1 WO 2023128197A1 KR 2022016542 W KR2022016542 W KR 2022016542W WO 2023128197 A1 WO2023128197 A1 WO 2023128197A1
Authority
WO
WIPO (PCT)
Prior art keywords
muscle
composition
group
dex
peanut
Prior art date
Application number
PCT/KR2022/016542
Other languages
English (en)
Korean (ko)
Inventor
강인혜
조상미
안도현
트엉티마이티엔
Original Assignee
제주대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020220133430A external-priority patent/KR102617562B1/ko
Application filed by 제주대학교 산학협력단 filed Critical 제주대학교 산학협력단
Publication of WO2023128197A1 publication Critical patent/WO2023128197A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Definitions

  • An object of the present invention is to provide a composition for improving, preventing or treating sarcopenia containing Udo peanut sprout extract as an active ingredient.
  • Muscle cells that form muscles are composed of myofilaments, which cause contraction by changing the size of the cells. When muscle tissue contracts, tension is generated, which is called muscle strength. Muscles are body organs that are responsible for the movement of objects, maintenance of posture, secretion of body fluids, and the like through these strengths.
  • Muscle atrophy or sarcopenia refers to loss of size and mass of muscle cells and muscle tissue that occurs under various catabolic conditions such as hormonal imbalance, severe injury, sepsis, cancer, and aging. . Muscular atrophy or sarcopenia causes muscle loss, resulting in muscle weakness and fatigue, and aggravating complications. Muscular atrophy or sarcopenia is diagnosed through creatine kinase (CK), electromyography, muscle biopsy, molecular biological genetic test, cytogenetic test, and the like.
  • CK creatine kinase
  • DEX dexamethasone
  • Dexamethasone is used to treat various diseases such as cancer, but it causes muscle atrophy or sarcopenia by decreasing the rate of protein synthesis in skeletal muscle and increasing the rate of protein breakdown through the ubiquitin-proteasome system.
  • Two muscle ubiquitin ligases are related to Atrogin-1 and MuRF1, and dexamethasone lowers MyoD (myogenic differentiation antigen) through Atrogin-1, and muscle mass is reduced through this mechanism.
  • the present inventors completed the present invention by confirming that the Udo peanut sprout extract can inhibit sarcopenia while conducting research on the physiological activity of the peanut sprout extract.
  • An object of the present invention is to provide a composition for muscle regeneration comprising peanut ( Arachis hypogaea L. ) sprout extract as an active ingredient.
  • an object of the present invention is to provide a pharmaceutical composition for preventing or treating muscle damage disease comprising peanut ( Arachis hypogaea L. ) sprout extract as an active ingredient.
  • an object of the present invention is to provide a composition for improving exercise capacity containing peanut ( Arachis hypogaea L. ) sprout extract as an active ingredient.
  • an object of the present invention is to provide a composition for increasing muscle mass containing peanut ( Arachis hypogaea L. ) sprout extract as an active ingredient.
  • an object of the present invention is a pharmaceutically effective amount of peanut ( Arachis hypogaea L. ) Muscle damage comprising the step of administering to a subject a pharmaceutical composition for preventing or treating muscle damage disease comprising a sprout extract as an active ingredient To provide a method for preventing or treating a disease.
  • peanut Arachis hypogaea L.
  • the present invention provides a composition for muscle regeneration comprising peanut ( Arachis hypogaea L. ) sprout extract as an active ingredient.
  • the present invention provides a pharmaceutical composition for preventing or treating muscle damage disease comprising an extract of peanut ( Arachis hypogaea L. ) sprout as an active ingredient.
  • the present invention provides a composition for improving exercise capacity containing peanut ( Arachis hypogaea L. ) sprout extract as an active ingredient.
  • the present invention provides a composition for increasing muscle mass containing peanut ( Arachis hypogaea L. ) sprout extract as an active ingredient.
  • the present invention is a pharmaceutically effective amount of peanut ( Arachis hypogaea L. ) Prevention of muscle damage disease comprising the step of administering to the subject a pharmaceutical composition for preventing or treating muscle damage disease containing as an active ingredient a sprout extract or provide a treatment method.
  • peanut Arachis hypogaea L.
  • the Udo peanut extract of the present invention treats muscle weakness induced by lipid accumulation and high-fat/high-sucrose diet, and when administered to a muscle-weakened mouse model, the Udo peanut extract improved strength and hanging ability, and was a muscle atrophy factor.
  • the inhibition of the expression of MuRF-1 (Muscle RING-finger protein-1) and muscle atrophy F-box (MAFbx/Atrogin-1) was confirmed.
  • POC1- ⁇ peroxisome proliferator-activated receptor gamma coactivator 1-alpha
  • 1 is a diagram showing the change in body weight after intraperitoneal injection of each of the Control group, Dex group, Dex+HFHS group, and Dex+HFHS+PSE group for 6 days.
  • Control group saline-fed mouse model
  • Dex group mouse model injected only with dexamethasone
  • Dex+HFHS group dexamethasone injection and HFHS: high-fat/high-sucrose diet
  • Dex+HFHS+PSE group dexamethasone injection and HFHS: high-fat/high-sucrose diet and Udo peanut sprout extracts (PSE) diet one mouse model
  • Figure 2 is a diagram showing the glucose tolerance test (Glucose tolerance test) of each of the Control group, Dex group, Dex+HFHS group, and Dex+HFHS+PSE group.
  • 3 is a diagram showing fasting blood glucose levels of each of the Control group, Dex group, Dex+HFHS group, and Dex+HFHS+PSE group.
  • 4 is a diagram showing the plasma triglyceride content of each of the Control group, Dex group, Dex+HFHS group, and Dex+HFHS+PSE group.
  • 5 is a diagram showing plasma total cholesterol in each of the Control group, Dex group, Dex+HFHS group, and Dex+HFHS+PSE group.
  • 6 is a diagram showing the forelimb grip strength against weight in each of the Control group, the Dex group, the Dex+HFHS group, and the Dex+HFHS+PSE group.
  • FIG. 7 is a diagram showing the degree of grip strength of the hind legs and front legs of each of the Control group, the Dex group, the Dex+HFHS group, and the Dex+HFHS+PSE groups.
  • FIG. 8 is a diagram showing the maintenance of grip strength against body weight in each of the Control group, Dex group, Dex+HFHS group, and Dex+HFHS+PSE group.
  • H&E hematoxylin and eosin
  • 10 is a diagram showing muscle fiber size of the quadriceps muscle using the MIPAR program of each of the Control group, Dex group, Dex+HFHS group, and Dex+HFHS+PSE group.
  • 11 is a diagram showing the mRNA expression level of muscle atrophy factors MuRF-1, Atrogin-1, and Myogenin in the gastrocnemius muscles of each of the Control group, Dex group, Dex+HFHS group, and Dex+HFHS+PSE group.
  • FIG. 12 is a diagram showing the protein expression of MuRF-1, Atrogin-1, and PGC1- ⁇ in the gastrocnemius muscles of each of the Control group, Dex group, Dex+HFHS group, and Dex+HFHS+PSE group.
  • FIG. 13 is a diagram showing the RNA expression levels of inflammatory markers TNF- ⁇ , IL-6, and IL-1 ⁇ in each of the Control group, Dex group, Dex+HFHS group, and Dex+HFHS+PSE group.
  • FIG. 14 is a diagram showing the mRNA expression levels of MuRF-1, Atrogin-1, and Myogenin in the quadriceps muscles of each of the Control group, Dex group, Dex+HFHS group, and Dex+HFHS+PSE group.
  • FIG. 15 is a diagram showing protein and mRNA expression of PGC1- ⁇ when each control, Dex+HFHS, and Dex+HFHS+PSE treatment was performed on skeletal muscle cells (C2C12).
  • FIG. 16 is a diagram showing cell viability when skeletal muscle cells (C2C12) are treated with Udo peanut extract (PSE).
  • 17 is a diagram showing mRNA expression of MuRF-1, Atrogin-1, and PGC1- ⁇ when each of Control, Dex+HFHS, and Dex+HFHS+PSE treatment was performed on skeletal muscle cells (C2C12).
  • terminal used in this specification are terms used to appropriately express preferred embodiments of the present invention, which may vary according to the intention of a user or operator or customs in the field to which the present invention belongs. Therefore, definitions of these terms will have to be made based on the content throughout this specification. Throughout the specification, when a part "includes" a certain component, it means that it may further include other components without excluding other components unless otherwise stated.
  • the extract according to the present invention may be obtained by extraction and separation from nature using extraction and separation methods known in the art, and the "extract" defined in the present invention is extracted from creation using an appropriate solvent, For example, a crude extract, a polar solvent-soluble extract, or a non-polar solvent-soluble extract are all included.
  • Any suitable solvent for extracting the extract from the creation may be used as long as it is a pharmaceutically acceptable organic solvent, and water or an organic solvent may be used, but is not limited thereto, for example, purified water, methanol ( Alcohols having 1 to 4 carbon atoms including methanol, ethanol, propanol, isopropanol, butanol, etc., acetone, ether, benzene, chloroform ( chloroform), ethyl acetate, methylene chloride, hexane and cyclohexane, etc. may be used alone or in combination.
  • methanol Alcohols having 1 to 4 carbon atoms including methanol, ethanol, propanol, isopropanol, butanol, etc.
  • acetone, ether, benzene, chloroform ( chloroform), ethyl acetate, methylene chloride, hexane and cyclohexane, etc. may be used alone or in combination
  • any one of methods such as hot water extraction, cold brew extraction, reflux cooling extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, and compression may be selected and used.
  • the desired extract may be additionally subjected to a conventional fractionation process or may be purified using a conventional purification method.
  • prevention may refer to any action that suppresses or delays the onset of a muscle-damaging disease by administering the pharmaceutical composition for preventing or treating a muscle-damaging disease according to the present invention to a subject.
  • treatment may refer to any action that improves or benefits the symptoms of a muscle-damaging disease by administering the composition of the present invention to a subject suspected of having a muscle-damaging disease.
  • the term “improvement” may refer to any activity that at least reduces a parameter related to the condition being treated, for example, the severity of a symptom.
  • the present invention provides a composition for muscle regeneration comprising peanut ( Arachis hypogaea L. ) sprout extract as an active ingredient.
  • the extract is extracted with any one solvent selected from the group consisting of water, C1 to C4 lower alcohol, or a mixed solvent thereof, but is not limited thereto.
  • the composition maintains metabolic parameters, but is not limited thereto.
  • the metabolism may be body weight, glucose tolerance test, fasting blood glucose level, plasma triglyceride content, or total cholesterol.
  • the composition increases muscle fibers, but is not limited thereto.
  • the muscle fibers are in the group consisting of quadriceps femoris, brachialis muscle, biceps brachii muscle, forearm muscle, rectus abdominis muscle, biceps femoris muscle, gracilis muscle, semitendinosus muscle, semimembranosus muscle, gastrocnemius muscle, vastus lateralis muscle, vastus medialis muscle, phalanx muscle, long head, medial muscle, etc. It may be 1 or more.
  • the composition promotes the expression of factors involved in myogenesis and differentiation, but is not limited thereto.
  • the factor may be at least one selected from the group consisting of MuRF-1 (Muscle RING-finger protein-1), atrogin-1, and myogenin.
  • the composition promotes the expression of factors involved in mitochondrial biogenesis and functional activity, but is not limited thereto.
  • the factor may be PGC1- ⁇ (peroxisome proliferator-activated receptor gamma coactivator 1-alpha).
  • the composition reduces the inflammatory factors TNF- ⁇ , IL-6 and IL-1 ⁇ , but is not limited thereto.
  • the composition increases grip strength and grip strength maintenance due to muscle regeneration, but is not limited thereto.
  • the present invention provides a pharmaceutical composition for preventing or treating muscle damage disease comprising peanut sprout extract as an active ingredient.
  • the pharmaceutical composition of the present invention may further include an adjuvant in addition to the active ingredient.
  • an adjuvant in addition to the active ingredient.
  • any one may be used without limitation, but, for example, Freund's complete adjuvant or incomplete adjuvant may be further included to increase immunity.
  • the pharmaceutical composition according to the present invention may be prepared in the form of incorporating the active ingredient into a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier includes carriers, excipients and diluents commonly used in the pharmaceutical field.
  • Pharmaceutically acceptable carriers usable in the pharmaceutical composition of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • the pharmaceutical composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories or sterile injection solutions according to conventional methods, respectively. .
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations contain at least one or more excipients such as starch, calcium carbonate, sucrose, lactose, and gelatin in addition to active ingredients. It can be prepared by mixing etc. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.
  • Liquid preparations for oral administration include suspensions, solutions for oral administration, emulsions, syrups, etc.
  • compositions for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations and suppositories.
  • Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents.
  • a base for suppositories witepsol, tween 61, cacao paper, laurin paper, glycerogelatin, and the like may be used.
  • composition according to the present invention can be administered to a subject by various routes. All modes of administration are contemplated, eg oral, intravenous, intramuscular, subcutaneous, intraperitoneal injection.
  • the pharmaceutical composition may be formulated into various oral or parenteral dosage forms.
  • Formulations for oral administration include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, granules, etc. chlorose, mannitol, sorbitol, cellulose and/or glycine), lubricants such as silica, talc, stearic acid and magnesium or calcium salts thereof and/or polyethylene glycol.
  • the tablet may contain a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidine, and in some cases starch, agar, alginic acid or a disintegrant or effervescent mixture, such as its sodium salt, and/or absorbents, colorants, flavors, and sweeteners.
  • a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidine, and in some cases starch, agar, alginic acid or a disintegrant or effervescent mixture, such as its sodium salt, and/or absorbents, colorants, flavors, and sweeteners.
  • the formulation may be prepared by conventional mixing, granulating or coating methods.
  • a typical formulation for parenteral administration is an injection formulation, and water, Ringer's solution, isotonic physiological saline or suspension may be used as a solvent for the injection formulation.
  • Sterile fixed oils of the above injectable preparations may be used as a solvent or suspension medium, and any bland fixed oil may be used for this purpose, including mono- and di-glycerides.
  • the formulation for injection may use a fatty acid such as oleic acid.
  • the disease consists of muscle strain, muscle rupture, muscle tearing, contusion, distortion, rotator cuff syndrome and myositis. It may be one or more muscle damage diseases selected from the group, but is not limited thereto.
  • the present invention provides a composition for improving exercise capacity containing peanut ( Arachis hypogaea L.) sprout extract as an active ingredient.
  • the present invention provides a composition for increasing muscle mass containing peanut ( Arachis hypogaea L.) sprout extract as an active ingredient.
  • the emotional behavior disorder is attention deficit disorder, hyperactivity disorder, interpersonal disorder, depressive disorder, antisocial disorder, anxiety disorder, attention deficit hyperactivity disorder (ADHD) disorder, conduct disorder, autism, obsessive-compulsive disorder, schizophrenia , Tourette's syndrome, etc., but one or more selected from the group consisting of, but is not limited thereto.
  • ADHD attention deficit hyperactivity disorder
  • the food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients like conventional Aa food compositions.
  • natural carbohydrates examples include monosaccharides such as glucose, fructose, and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrins, cyclodextrins, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • natural flavoring agents thaumatin
  • stevia extracts eg rebaudioside A, glycyrrhizin, etc.
  • synthetic flavoring agents sacharin, aspartame, etc.
  • the food composition of the present invention can be formulated in the same way as the pharmaceutical composition and used as a functional food or added to various foods.
  • Foods to which the composition of the present invention can be added include, for example, beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gum, candy, ice cream, alcoholic beverages, vitamin complexes and health supplements, etc. there is
  • the food composition in addition to the active ingredient extract, various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, Alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, and the like may be contained.
  • the food composition of the present invention may contain fruit flesh for preparing natural fruit juice, fruit juice beverages, and vegetable beverages.
  • the functional food composition of the present invention can be prepared and processed in the form of tablets, capsules, powders, granules, liquids, pills and the like.
  • 'health functional food composition' refers to a food manufactured and processed using raw materials or ingredients having useful functionality for the human body according to Health Functional Food Act No. 6727, and the structure and function of the human body It refers to intake for the purpose of obtaining useful effects for health purposes such as regulating nutrients or physiological functions.
  • the health functional food of the present invention may contain ordinary food additives, and the suitability as a food additive is determined according to the general rules of the Food Additive Code and General Test Methods approved by the Food and Drug Administration, unless otherwise specified. It is judged according to standards and standards.
  • Examples of the items listed in the 'Food Additive Code' include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon pigment, licorice extract, crystalline cellulose, kaoliang pigment, and guar gum; and mixed preparations such as sodium L-glutamate preparations, noodle-added alkali preparations, preservative preparations, and tar color preparations.
  • chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid
  • natural additives such as persimmon pigment, licorice extract, crystalline cellulose, kaoliang pigment, and guar gum
  • mixed preparations such as sodium L-glutamate preparations, noodle-added alkali preparations, preservative preparations, and tar color preparations.
  • a health functional food in the form of a tablet is obtained by granulating a mixture obtained by mixing the active ingredient of the present invention with an excipient, a binder, a disintegrant, and other additives in a conventional manner, and then adding a lubricant or the like to compression molding, or as described above.
  • the mixture can be directly compression molded.
  • the health functional food in the form of a tablet may contain a flavoring agent and the like as needed.
  • hard capsules can be prepared by filling a mixture in which the active ingredient of the present invention is mixed with additives such as excipients in a normal hard capsule. It can be prepared by filling the mixture mixed with gelatin in a capsule base.
  • the soft capsule may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, if necessary.
  • a plasticizer such as glycerin or sorbitol
  • a colorant such as a preservative, and the like
  • the health functional food in the form of a pill can be prepared by molding a mixture of the active ingredient of the present invention mixed with an excipient, a binder, a disintegrant, etc. by a conventionally known method, and can be coated with sucrose or other coating agent if necessary, Alternatively, the surface may be coated with a material such as starch or talc.
  • Health functional food in the form of granules can be prepared in granular form by a conventionally known method of mixing the active ingredient of the present invention with excipients, binders, disintegrants, etc., and, if necessary, flavoring agents, flavoring agents, etc. can
  • the present invention is a pharmaceutically effective amount of peanut ( Arachis hypogaea L. ) Prevention or treatment of muscle damage disease comprising the step of administering to a subject a pharmaceutical composition for preventing or treating muscle damage disease containing as an active ingredient a sprout extract provides a way
  • the present invention provides a method for preventing or treating muscle damage disease comprising the step of administering a pharmaceutically effective amount of the peanut ( Arachis hypogaea L. ) sprout extract to a subject.
  • the pharmaceutical composition of the present invention is administered in a therapeutically effective amount or a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is dependent on the type and severity of the subject, age, sex, activity of the drug, and drug. sensitivity, time of administration, route of administration and excretion rate, duration of treatment, factors including concomitantly used drugs, and other factors well known in the medical field.
  • Example 1-1 Laboratory chemicals and sample preparation
  • the present inventors freshly diluted peanut sprout extracts (Peanut sprout extracts, PSE) stocks in phosphate buffered saline (PBS) before using them in animal experiments.
  • PSE peanut sprout extracts
  • Example 1-2 animals and diet
  • mice Six-week-old male C57BL/6 mice were purchased from ORIENT BIO Animal Center (Seongnam-si, Korea) and maintained on a 12-hour dark/light cycle while consuming food and water freely. Prior to the experiments, mice were acclimatized for 1 week by oral gavage, and all animal experiments and experimental protocols were approved by the Jeju National University Animal Care Committee (IACUC) (2021-0026) and were performed in accordance with institutional guidelines. Eight-week-old male C57BL/6 mice were fed a low fat diet (LF) or high fat/high sugar diet with saline or Peanut sprout extracts (PSE) (10 mg/kg body weight (BW)) for 10 weeks. (high-fat/high-sucrose diet, HFHS).
  • LF low fat diet
  • PSE Peanut sprout extracts
  • Dexamethasone (Dex, 10 mg/kg BW) of the present invention was administered by intraperitoneal injection for 6 days to aggravate muscle atrophy in rats: (i) control, (ii) Dex (iii) Dex+HFHS and (iv) Experiments were conducted by administering Dex+HFHS+PSE to mouse animal models. After the experiment was completed, C57BL/6 mice were fasted for 12 hours and then sacrificed under carbon dioxide anesthesia. Blood, liver, epididymal fat, quadriceps and gastrocnemius muscles were collected from the sacrificed mice.
  • Low-fat diet (LF, 11% kcal fat) and high-fat diet (HF, 60% kcal fat) preparations were modified to Table 1 as the AIN-93G diet.
  • High sucrose water (HS) was prepared by autoclaving 20% sucrose water at 115 °C for 15 minutes. Body weight and food intake were measured weekly.
  • mice were subjected to a glucose tolerance test (GTT) at the 9th week of the experiment. After the mice were fasted for 12 hours, a 10% D-glucose solution (1 g/kg BW) was intraperitoneally injected. A blood glucose meter (Contour plus, BAYER) was used at 0, 15, 30, 60 and 120 minutes to measure blood glucose levels.
  • GTT glucose tolerance test
  • Example 1-4 Plasma biochemistry
  • Plasma Plasma was obtained by adding heparin to the collected blood and centrifuging at 10,000 rpm for 10 minutes. Pharmaceutical Co., Ltd., Seoul, Korea) was used to measure the absorbance at OD 500 and 550 nm according to the manufacturing protocol.
  • the grip strength of the rats was measured with a Grip Strength Meter (Ugo-Basile).
  • the grip strength of the forelimb was measured three times and the largest value was used, and the same was applied when the forelimb and hindlimb were measured together.
  • the duration of hanging on the wire mesh of the mouse was measured when the mouse was turned over after allowing the mouse to hold the wire mesh by itself.
  • each mouse was measured at least three times, and the largest value was used.
  • Example 1-6 Hematoxylin and Eosin (H&E) staining and quantification of adipocyte, steatosis and muscle fiber size
  • mice At necropsy, epididymal fat, liver and quadriceps were isolated from mice and flash-fixed in 10% formalin buffer. Paraffin-embedded tissues were cut into 5-7 ⁇ m sections and stained with hematoxylin and eosin (H&E). Bright-field images were captured with an Invitrogen microscope (InvitrogenTM EVOSTM FL Digital Inverted Fluorescence Microscope, Invitrogen, CA, USA) at 10x and 20x magnification.
  • Invitrogen microscope InvitrogenTM EVOSTM FL Digital Inverted Fluorescence Microscope, Invitrogen, CA, USA
  • H&E staining of epididymal adipose tissue was quantified to measure adipocyte size.
  • Image J and Adiposoft of National Institutes of Health (NIH) were used.
  • MIPAR software MIPARTM, Worthington, OH, USA was used to quantify steatosis in H&E-stained liver tissue and muscle fibers in H&E-stained quadriceps.
  • Example 1-7 cell culture
  • C2C12 myoblast cells (American Type Culture Collection (ATCC), Manassas, VA, USA) were cultured in a basal medium containing 10% FBS in DMEM containing 1% P/S. After C2C12 myoblasts reached 80-90% confluence (referred to as day 0), the growth medium was changed from DMEM with 1% P/S to differentiation medium containing 2% HS to differentiate the cells into myotubes. Thereafter, the cells were maintained for up to 4-6 days while changing the medium every other day.
  • ATCC American Type Culture Collection
  • VA Manassas, VA, USA
  • Skeletal muscle cells (C2C12) were cultured in 96-well plates at a seeding density of approximately 20,000 cells/well in growth medium. Cells were incubated for 24 hours with DMSO or different concentrations of Udo peanut shoot extract (PSE). Then, the cells were replaced with fresh medium containing 10% EZ-cytox solution and incubated at 37°C. Plates were read at OD 450 nm using a microplate reader for 30 minutes to 4 hours.
  • Example 1-9 mRNA analysis by real-time polymerase chain reaction (real-time PCR)
  • RNA from muscle and cells was extracted with Trizol reagent (Invitrogen).
  • HPRT Hypoxanthine-guanine phosphoribosyltransferase
  • RPLP0/36B4 ribosomal protein lateral stem subunit P0
  • Example 1-10 Protein isolation and western blotting
  • Tissue samples were harvested and homogenized with a homogenizer in ice-col radioimmunoprecipitation (RIPA) assay lysis buffer containing protease and phosphatase inhibitor hops.
  • C2C12 cells were scraped with ice-cold RIPA assay lysis buffer containing protease and phosphatase inhibitors. Then, the supernatant was collected by centrifugation at 10,000 rpm and 4°C for 10 minutes, and 10-15 ⁇ g of protein was separated using 8-10% SDS-PAGE and the protein was separated in Tris-buffered saline/Tween 20.
  • RIPA radioimmunoprecipitation
  • PVDF polyvinylidene difluoride
  • HFHS high-fat/high-sugar

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a pour objectif de fournir une composition pour prévenir ou traiter des maladies musculaires, comprenant un extrait de germes de cacahuète de Jeju Udo en tant que principe actif, l'extrait de germe de cacahuète de Jeju Udo étant utilisé pour traiter une faiblesse musculaire induite par l'accumulation de lipides et une consommation élevée de graisse et de saccharose. Il a été identifié que, lorsqu'il est administré à un modèle de souris avec des muscles affaiblis, l'extrait de germe de cacahuète de Jeju Udo améliore la force de préhension et les performances de suspension et inhibe l'expression d'un facteur d'atrophie musculaire de la protéine RING-finger-1 (MuRF-1) et de l'atrophie musculaire F-box (MAFbx)/atrogine-1. En outre, il a été identifié que la présente invention augmente l'expression du coactivateur du récepteur gamma activé par les proliférateurs de peroxysomes 1-alpha (PGC1-α), qui est un marqueur de la biogenèse mitochondriale et de l'activation fonctionnelle, dans les cellules musculaires squelettiques (C2C12) afin d'atténuer l'atrophie des muscles squelettiques et d'activer la fonction mitochondriale, et peut donc être utilisée efficacement dans des activités connexes.
PCT/KR2022/016542 2021-12-31 2022-10-27 Composition pour soulager, prévenir ou traiter la sarcopénie, comprenant un extrait de germe de cacahuète de jeju udo en tant que principe actif WO2023128197A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2021-0193894 2021-12-31
KR20210193894 2021-12-31
KR1020220133430A KR102617562B1 (ko) 2021-12-31 2022-10-17 우도 땅콩 새싹 추출물을 유효성분으로 함유하는 근감소증의 개선, 예방 또는 치료용 조성물
KR10-2022-0133430 2022-10-17

Publications (1)

Publication Number Publication Date
WO2023128197A1 true WO2023128197A1 (fr) 2023-07-06

Family

ID=86999317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/016542 WO2023128197A1 (fr) 2021-12-31 2022-10-27 Composition pour soulager, prévenir ou traiter la sarcopénie, comprenant un extrait de germe de cacahuète de jeju udo en tant que principe actif

Country Status (1)

Country Link
WO (1) WO2023128197A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060127894A (ko) * 2004-02-10 2006-12-13 아사히비루 가부시키가이샤 근장력 증강제
KR20190003571A (ko) * 2016-04-27 2019-01-09 소시에떼 덱스플로와따시옹 더 쁘로뒤 뿌르 레 엥뒤스트리 쉬미끄, 에스. 에. 페. 페. 이. 세. 근육 손상 및 피로를 예방하기 위한 조성물의 능력을 평가하기 위한 방법 및 음식 보충제 및 약제

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060127894A (ko) * 2004-02-10 2006-12-13 아사히비루 가부시키가이샤 근장력 증강제
KR20190003571A (ko) * 2016-04-27 2019-01-09 소시에떼 덱스플로와따시옹 더 쁘로뒤 뿌르 레 엥뒤스트리 쉬미끄, 에스. 에. 페. 페. 이. 세. 근육 손상 및 피로를 예방하기 위한 조성물의 능력을 평가하기 위한 방법 및 음식 보충제 및 약제

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAN, SANG HYEONG: "CHO, Sang Mi, A Master's Degree Student at Jeju National University, Awarded at the ‘2021 KFN International Symposium and Annual Meeting", KOREA LECTURER NEWS, 1 December 2021 (2021-12-01), XP009547538 *
JO SANG MI, DOHYUN AHN, TIEN THI MY TRUONG, SEOK HEE SEO, INHAE KANG: "The potential protective effects of peanut sprout extract and it`s main component p-coumaric acid on dexamethasone-induced skeletal muscle atrophy", 2021 KFN INTERNATIONAL SYMPOSIUM AND ANNUAL MEETING, 1 October 2021 (2021-10-01), pages 357, XP093076121 *
SEO SEOK HEE, JO SANG-MI, TRUONG TIEN THI MY, ZHANG GUIGUO, KIM DONG-SHIN, LEE MYOUNGSOOK, LEE YUNKYOUNG, KANG INHAE: "Peanut sprout rich in p -coumaric acid ameliorates obesity and lipopolysaccharide-induced inflammation and the inhibition of browning in adipocytes via mitochondrial activation", FOOD & FUNCTION, R S C PUBLICATIONS, GB, vol. 12, no. 12, 21 June 2021 (2021-06-21), GB , pages 5361 - 5374, XP093076120, ISSN: 2042-6496, DOI: 10.1039/D1FO00342A *

Similar Documents

Publication Publication Date Title
WO2019199094A1 (fr) Nouvelle souche de bifidobacterium longum ou de lactobacillus rhamnosus ayant pour effet de prévenir ou de traiter l'obésité, et utilisation correspondante
WO2014058142A1 (fr) Composition pharmaceutique contenant un extrait d'aster glehni en tant que principe actif pour la prévention et le traitement de l'obésité et de troubles métaboliques
WO2019226015A1 (fr) Composition pour favoriser la myogenèse, contenant un extrait de ginseng traité
WO2020091166A1 (fr) Nouvelles bactéries lactiques et leur utilisation
WO2015002391A1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
WO2010058926A2 (fr) Composition pharmaceutique contenant un extrait de gingembre ou du shogaol
WO2017014502A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par il-6 comprenant un extrait de fleur de rosa rugosa en tant que substance active
WO2016080691A1 (fr) Composition pharmaceutique comprenant des extraits de symplococs chinesis et astragalus membranaceus pour prévenir et traiter l'arthrite, et son procédé de préparation
WO2021230581A1 (fr) Découverte d'une nouvelle akkermansia muciniphila ak32 et application correspondante pour la prévention ou le traitement d'une lésion intestinale
WO2016186349A2 (fr) Composition, contenant un extrait de quisaqualis indica, pour la prévention ou le traitement de l'hyperplasie prostatique
WO2020231031A2 (fr) Composition comprenant du lactobacillus acidophilus pour prévenir, atténuer ou traiter l'arthromyalgie, les céphalées ou la sécheresse vaginale chez les femmes climatériques
WO2023128197A1 (fr) Composition pour soulager, prévenir ou traiter la sarcopénie, comprenant un extrait de germe de cacahuète de jeju udo en tant que principe actif
WO2016093613A2 (fr) Composition pour la prévention ou le traitement d'une perte de poids anormale, contenant un extrait de pelure de mandarine satsuma
WO2016148545A1 (fr) Composition pour prévenir ou améliorer des symptômes d'andropause
WO2022039514A1 (fr) Composition pour le traitement de maladies cérébrales comprenant lactobacillus sakei ou des vésicules extracellulaires dérivées de celui-ci en tant que principe actif
WO2018008973A1 (fr) Composition comprenant un extrait de forsythiae fructus en tant que principe efficace pour prévenir, améliorer ou traiter la neuropathie périphérique
WO2014133276A1 (fr) Composition contenant, en tant que composants actifs, menispermum dauricum, un extrait de menispermum dauricum, un biofilm de menispermum dauricum, ou un extrait de liquide enzymatique de malt de menispermum dauricum pour prévenir ou traiter l'anorexie
WO2020231030A2 (fr) Composition comprenant du lactobacillus acidophilus pour prévenir, atténuer ou traiter la nervosité, les fourmillements, l'insomnie, les vertiges ou la fatigue chez les femmes ménopausées
KR102617562B1 (ko) 우도 땅콩 새싹 추출물을 유효성분으로 함유하는 근감소증의 개선, 예방 또는 치료용 조성물
WO2021040416A1 (fr) Composition pharmaceutique pour prévenir ou traiter la perte osseuse induite par des maladies métaboliques osseuses, comprenant un extrait d'artemisia scoparia en tant que principe actif
WO2019208914A1 (fr) Composition comprenant portulaca oleracea l. en tant que principe actif pour favoriser la croissance osseuse
WO2023153902A1 (fr) Composition pour inhiber la différenciation de pré-adipocytes et l'accumulation de lipides comprenant enterococcus faecalis, fluide de culture correspondant ou cellules tuées correspondantes en tant que principe actif
WO2022239916A1 (fr) Nouvelle souche de bifidobacterium longum et son utilisation
WO2022173273A1 (fr) Composition comprenant un extrait d'aronia pour prévenir ou traiter une maladie musculaire
WO2021033994A1 (fr) Composition comprenant un extrait de salvia miltiorrhiza ou de paeonia lactiflora utilisé comme principe actif pour la prévention ou le traitement d'un trouble du métabolisme des lipides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22916351

Country of ref document: EP

Kind code of ref document: A1